BIOSUMMITS (0804.560.659), Inactive: annual accounts and directors

BIOSUMMITS

KBO/BCE: BE 0804.560.659

Line	2025	2024
Balance sheet: assets
Total assets`20/58`	84,332	98,391
Fixed assets`21/28`	4,280	5,462
Tangible fixed assets`22/27`	4,280	5,462
Furniture and vehicles`24`	1,968	2,555
Other tangible fixed assets`26`	2,312	2,907
Current assets`29/58`	80,052	92,929
Amounts receivable within one year`40/41`	6,421	10,465
Trade receivables`40`	-	10,461
Other amounts receivable`41`	6,421	4
Cash at bank and in hand`54/58`	73,631	81,305
Deferred charges and accrued income`490/1`	-	1,159
Balance sheet: equity and liabilities
Total equity and liabilities`10/49`	84,332	98,391
Equity`10/15`	71,479	64,833
Contributions`10/11`	2,000	2,000
Reserves`13`	69,479	62,833
Distributable reserves`133`	69,479	62,833
Amounts payable`17/49`	12,852	33,559
Amounts payable within one year`42/48`	12,852	33,559
Trade debts`44`	3,519	507
Suppliers`440/4`	3,519	507
Taxes, remuneration and social security`45`	500	30,838
Taxes`450/3`	500	30,838
Other amounts payable`47/48`	8,833	2,213
Income statement
Gross operating margin`9900`	19,927	92,821
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets`630`	1,183	1,801
Other operating charges`640/8`	186	540
Operating profit (loss)`9901`	18,558	90,480
Financial charges`65/66B`	40	79
Recurring financial charges`65`	40	79
Profit (loss) for the period before taxes`9903`	18,518	90,401
Income taxes`67/77`	3,038	25,076
Profit (loss) for the period`9904`	15,480	65,325
Profit (loss) for the period to be appropriated`9905`	15,480	65,325
Appropriation of the result
Profit (loss) to be appropriated`9906`	15,480	65,325
Transfer to equity`691/2`	6,647	62,833
To other reserves`6921`	6,647	62,833
Profit to be distributed`694/7`	8,833	2,492
Return on contributions (dividend)`694`	833	2,492
Directors or managers`695`	8,000	-
Document	PDF	PDF

Financial year	Type	Filed	Reference	Document
31-12-2025	micro format	08-06-2026	2026-00142699	PDF
31-12-2024	micro format	27-08-2025	2025-00411530	PDF

Line	2025	2024
EBITDA	19,741	92,281
Cash flow	16,662	67,126
Investment in fixed assets (approximation)	0	5,913
Change in cash	-7,674	-
Working capital	67,200	59,371
Solvency	84.8%	65.9%
Current ratio	6.23	2.77
Debt to equity	0.18	0.52
ROE	21.7%	100.8%
ROA	18.4%	66.4%
Interest coverage	over 100	over 100

Item	2025	2024
Tangible fixed assets	-	€5,913
Depreciation and write-downs of the year	€1,183	€1,801

BIOSUMMITS

Overview

Lifetime

Key points

Equity

Liquidity

Board and ownership

Recent changes

Official details

Annual accounts 2025

Insights on BIOSUMMITS

Financials

Annual accounts 2025

Balance sheet

Change in equityin euro

Change in cashin euro

Filed annual accounts

Filings

Key figures and ratios

Investments

Insights on BIOSUMMITS

Board & ownership

Last board

Mandates through the years

Control

Capital

Articles of association

Shareholders

Network & group

No group

Timeline

History

Company details

Purpose according to the articles of association

Buildings and parcels at the address

Dissolved and wound up on 15 June 2026

Location

Parcels